hinge health inc - HNGE
HNGE
Close Chg Chg %
115.93 -1.63 -1.41%
Open Market
114.30
-1.63 (1.41%)
Volume: 682.51K
Last Updated:
Nov 6, 2026, 1:59 PM EDT
Company Overview: hinge health inc - HNGE
HNGE Key Data
| Open $115.94 | Day Range 111.00 - 118.70 |
| 52 Week Range 30.08 - 124.93 | Market Cap $9.75B |
| Shares Outstanding 80.69M | Public Float 53.20M |
| Beta 1.18 | Rev. Per Employee N/A |
| P/E Ratio 60.88 | EPS $2.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.08M |
HNGE Performance
| 1 Week | 1.45% | ||
| 1 Month | 12.71% | ||
| 3 Months | 29.83% | ||
| 1 Year | 160.69% | ||
| 5 Years | N/A |
HNGE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
About hinge health inc - HNGE
Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. It leverages software, including artificial intelligence, to automate care for joint and muscle health, delivering member experience, member outcomes, and cost reductions for its clients. The company was founded by Daniel Perez and Gabriel Mecklenburg in 2014 and is headquartered in San Francisco, CA.
HNGE At a Glance
Hinge Health, Inc.
455 Market Street
San Francisco, California 94105
| Phone | 1-415-726-2206 | Revenue | 587.86M | |
| Industry | Packaged Software | Net Income | -424,087,000.00 | |
| Sector | Technology Services | 2025 Sales Growth | 50.577% | |
| Fiscal Year-end | 12 / 2026 | Employees | 143 | |
| View SEC Filings |
HNGE Valuation
| P/E Current | 58.85 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.256 |
| Price to Book Ratio | 20.584 |
| Price to Cash Flow Ratio | 21.45 |
| Enterprise Value to EBITDA | -6.571 |
| Enterprise Value to Sales | 5.99 |
| Total Debt to Enterprise Value | 0.002 |
HNGE Efficiency
| Revenue/Employee | 4,110,909.091 |
| Income Per Employee | -2,965,643.357 |
| Receivables Turnover | 8.899 |
| Total Asset Turnover | 0.827 |
HNGE Liquidity
| Current Ratio | 1.387 |
| Quick Ratio | 1.29 |
| Cash Ratio | 1.004 |
HNGE Profitability
| Gross Margin | 79.649 |
| Operating Margin | -92.032 |
| Pretax Margin | -89.692 |
| Net Margin | -72.141 |
| Return on Assets | -59.652 |
| Return on Equity | -106.657 |
| Return on Total Capital | -109.704 |
| Return on Invested Capital | -105.192 |
HNGE Capital Structure
| Total Debt to Total Equity | 2.124 |
| Total Debt to Total Capital | 2.08 |
| Total Debt to Total Assets | 1.077 |
| Long-Term Debt to Equity | 2.136 |
| Long-Term Debt to Total Capital | 0.987 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Hinge Health Inc - HNGE
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
Sales/Revenue
| - | 292.73M | 390.40M | 587.86M | |
Sales Growth
| - | - | +33.37% | +50.58% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 98.55M | 89.81M | 119.64M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 5.63M | 5.95M | 5.13M | |
Depreciation
| - | 5.23M | 5.55M | 4.23M | |
Amortization of Intangibles
| - | 400.00K | 400.00K | 900.00K | |
COGS Growth
| - | - | -8.87% | +33.21% | - |
Gross Income
| - | 194.18M | 300.59M | 468.22M | |
Gross Income Growth
| - | - | +54.80% | +55.77% | - |
Gross Profit Margin
| - | +66.33% | +77.00% | +79.65% |
| 2023 | 2024 | 2025 | 5-year trend | ||
|---|---|---|---|---|---|
SG&A Expense
| - | 324.69M | 325.02M | 1.01B | |
Research & Development
| - | 110.06M | 97.49M | 368.14M | |
Other SG&A
| - | 214.63M | 227.53M | 641.11M | |
SGA Growth
| - | - | +0.10% | +210.51% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 7.48M | 5.35M | - |
EBIT after Unusual Expense
| - | (130.51M) | (31.91M) | (546.37M) | |
Non Operating Income/Expense
| - | 21.97M | 20.65M | 19.11M | |
Non-Operating Interest Income
| - | - | - | 18.68M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | (108.55M) | (11.26M) | (527.26M) | |
Pretax Income Growth
| - | - | +89.63% | -4,584.28% | - |
Pretax Margin
| - | -37.08% | -2.88% | -89.69% | |
Income Tax
| - | (405.00K) | 677.00K | 998.00K | |
Income Tax - Current - Domestic
| - | - | 624.00K | 471.00K | - |
Income Tax - Current - Foreign
| - | 68.00K | 638.00K | 474.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | (473.00K) | (585.00K) | 53.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | 104.17M | - |
Consolidated Net Income
| - | (108.14M) | (11.93M) | (424.09M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | (108.14M) | (11.93M) | (424.09M) | |
Net Income Growth
| - | - | +88.97% | -3,453.90% | - |
Net Margin Growth
| - | -36.94% | -3.06% | -72.14% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | (108.14M) | (11.93M) | (424.09M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | (108.14M) | (11.93M) | (424.09M) | |
EPS (Basic)
| - | -1.3861 | -0.153 | -5.3566 | |
EPS (Basic) Growth
| - | - | +88.96% | -3,401.05% | - |
Basic Shares Outstanding
| - | 78.02M | 78.02M | 79.17M | |
EPS (Diluted)
| - | -1.3861 | -0.153 | -5.3566 | |
EPS (Diluted) Growth
| - | - | +88.96% | -3,401.05% | - |
Diluted Shares Outstanding
| - | 78.02M | 78.02M | 79.17M | |
EBITDA
| - | (124.89M) | (18.48M) | (535.89M) | |
EBITDA Growth
| - | - | +85.20% | -2,799.98% | - |
EBITDA Margin
| - | -42.66% | -4.73% | -91.16% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 116.375 | |
| Number of Ratings | 18 | Current Quarters Estimate | 0.728 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | 2.518 | |
| Last Quarter’s Earnings | 0.71 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.62 | Next Fiscal Year Estimate | 3.129 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 11 | 12 | 12 |
| Mean Estimate | 0.73 | 0.64 | 2.52 | 3.13 |
| High Estimates | 0.78 | 0.69 | 2.73 | 3.43 |
| Low Estimate | 0.57 | 0.56 | 2.44 | 2.93 |
| Coefficient of Variance | 7.34 | 6.75 | 2.83 | 4.82 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 14 | 13 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 2 | 2 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Hinge Health Inc - HNGE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Hinge Health Inc - HNGE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 14, 2026 | James W. Budge Chief Financial Officer | 342,348 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $101.53 per share | 34,758,592.44 |
| Oct 14, 2026 | James W. Budge Chief Financial Officer | 320,646 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.54 per share | 32,879,040.84 |
| Oct 14, 2026 | James W. Budge Chief Financial Officer | 306,148 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.48 per share | 31,680,195.04 |
| Oct 14, 2026 | James W. Budge Chief Financial Officer | 296,728 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.34 per share | 30,960,599.52 |
| Oct 14, 2026 | Deer Management Co. LLC Director | N/A | Open market or private sale of non-derivative or derivative security | 0.00 |
| Oct 14, 2026 | Deer Management Co. LLC Director | N/A | Open market or private sale of non-derivative or derivative security | 0.00 |
| Oct 14, 2026 | Gabriel Mecklenburg Director | 200,000 | Conversion of derivative security | 0.00 |
| Oct 14, 2026 | Gabriel Mecklenburg Director | 191,358 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $101.53 per share | 19,428,577.74 |
| Oct 14, 2026 | Gabriel Mecklenburg Director | 99,856 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.53 per share | 10,238,235.68 |
| Oct 14, 2026 | Gabriel Mecklenburg Director | 39,868 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.48 per share | 4,125,540.64 |
| Oct 14, 2026 | Gabriel Mecklenburg Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.34 per share | 0.00 |
| Oct 8, 2026 | Daniel Perez CEO & Co-Founder; Director | 4,100 | Conversion of derivative security | 0.00 |
| Oct 8, 2026 | Daniel Perez CEO & Co-Founder; Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.2 per share | 0.00 |
| Oct 7, 2026 | Tyler Renwick Sloat Director | 10,385 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $92.56 per share | 961,235.60 |
| Sep 15, 2026 | Gabriel Mecklenburg Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $90.46 per share | 0.00 |